Search Results

Inhibikase’s setback continues biopharma’s losing streak against Parkinson’s, marked by several clinical failures and abandoned assets in recent months.

The report comes just two days after Novartis announced its own Parkinson’s drug failure.

This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are still chasing these multi-billion-dollar markets.

Halia Therapeutics, NodThera and Gain Therapeutics target neuroinflammatory processes in hopes of modifying the course of Parkinson’s progression.

Results from TEMPO-1, which showed that tavapadon significantly improved motor symptoms in patients with Parkinson’s disease, will help AbbVie as it builds a regulatory case for the D1/D5 dopamine receptor agonist.

Spur Therapeutics, formerly Freeline Therapeutics, today announced new data from its GBA1 Parkinson’s disease research program demonstrating that its rationally engineered GCase85 enzyme reduces the accumulation of α-Synuclein, a protein that plays a significant role in the development and progression of Parkinson’s disease, more effectively than wildtype glucocerebrosidase (GCase) in in vitro studies.

Lucy Therapeutics, Inc. today announced it has raised $12.5 million in additional funding led by existing investors Engine Ventures and Safar Partners with new participation from Bill Gates, Parkinson’s UK, and the Michael J. Fox Foundation, which provided a $2 million non-dilutive grant.